287 related articles for article (PubMed ID: 23706767)
1. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.
Gomes AR; Zhao F; Lam EW
Chin J Cancer; 2013 Jul; 32(7):365-70. PubMed ID: 23706767
[TBL] [Abstract][Full Text] [Related]
2. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Zhao F; Lam EW
Front Med; 2012 Dec; 6(4):376-80. PubMed ID: 23124885
[TBL] [Abstract][Full Text] [Related]
3. Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.
Nestal de Moraes G; Bella L; Zona S; Burton MJ; Lam EW
Curr Drug Targets; 2016; 17(2):164-77. PubMed ID: 25418858
[TBL] [Abstract][Full Text] [Related]
4. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.
Wilson MS; Brosens JJ; Schwenen HD; Lam EW
Curr Drug Targets; 2011 Aug; 12(9):1256-66. PubMed ID: 21443467
[TBL] [Abstract][Full Text] [Related]
5. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.
Shukla S; Bhaskaran N; Maclennan GT; Gupta S
Prostate; 2013 Oct; 73(14):1507-17. PubMed ID: 23765843
[TBL] [Abstract][Full Text] [Related]
8. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade.
Yung MM; Chan DW; Liu VW; Yao KM; Ngan HY
BMC Cancer; 2013 Jul; 13():327. PubMed ID: 23819460
[TBL] [Abstract][Full Text] [Related]
9. FOXO3a: a novel player in thyroid carcinogenesis?
Karger S; Weidinger C; Krause K; Sheu SY; Aigner T; Gimm O; Schmid KW; Dralle H; Fuhrer D
Endocr Relat Cancer; 2009 Mar; 16(1):189-99. PubMed ID: 18845647
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy: tailoring cancer treatment.
Yan M; Liu QQ
Chin J Cancer; 2013 Jul; 32(7):363-4. PubMed ID: 23823626
[TBL] [Abstract][Full Text] [Related]
11. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
13. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
[TBL] [Abstract][Full Text] [Related]
14. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.
Yao S; Fan LY; Lam EW
Semin Cancer Biol; 2018 Jun; 50():77-89. PubMed ID: 29180117
[TBL] [Abstract][Full Text] [Related]
15. Forkhead box M1 transcription factor: a novel target for cancer therapy.
Wang Z; Ahmad A; Li Y; Banerjee S; Kong D; Sarkar FH
Cancer Treat Rev; 2010 Apr; 36(2):151-6. PubMed ID: 20022709
[TBL] [Abstract][Full Text] [Related]
16. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.
van Boxtel R; Gomez-Puerto C; Mokry M; Eijkelenboom A; van der Vos KE; Nieuwenhuis EE; Burgering BM; Lam EW; Coffer PJ
Cell Death Differ; 2013 Sep; 20(9):1219-29. PubMed ID: 23832113
[TBL] [Abstract][Full Text] [Related]
17. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
Buchner M; Park E; Geng H; Klemm L; Flach J; Passegué E; Schjerven H; Melnick A; Paietta E; Kopanja D; Raychaudhuri P; Müschen M
Nat Commun; 2015 Mar; 6():6471. PubMed ID: 25753524
[TBL] [Abstract][Full Text] [Related]
18. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
Yang JY; Chang CJ; Xia W; Wang Y; Wong KK; Engelman JA; Du Y; Andreeff M; Hortobagyi GN; Hung MC
Cancer Res; 2010 Jun; 70(11):4709-18. PubMed ID: 20484037
[TBL] [Abstract][Full Text] [Related]
19. Activated phosphatidylinositol 3-kinase/Akt inhibits the transition of endothelial progenitor cells to mesenchymal cells by regulating the forkhead box subgroup O-3a signaling.
Zhang Z; Zhang T; Zhou Y; Wei X; Zhu J; Zhang J; Wang C
Cell Physiol Biochem; 2015; 35(4):1643-53. PubMed ID: 25824462
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
